RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Predicting outcomes in the orthotic management of painful, idiopathic pes cavus.

OBJECTIVE: People who have extremely high arched feet are subject to substantial foot pain, despite a lack of obvious pathology. Customized foot orthoses improve pain and function and reduce foot pressure, but their specificity is unclear. This study sought to identify predictive variables for improvement and to determine whether changes in foot pressure were correlated to changes in pain and function.

DESIGN: Retrospective analysis of data from a randomized controlled clinical trial.

SETTING: Clinical movement analysis laboratory, School of Physiotherapy, University of Sydney.

PARTICIPANTS: Subjects with painful, idiopathic pes cavus.

INTERVENTIONS: Sixty-six subjects received customized foot orthoses; sixty-seven subjects were allocated a sham intervention.

MAIN OUTCOME MEASURES: Foot pressure data, location and intensity of pain, Foot Posture Index values, and anthropometric and quality of life variables.

RESULTS: No relationship between change in foot pressure and change in symptoms was found in either group. No individual characteristics were linked to improvement. Subjects who improved most had substantial pain, lowest function scores, and lowest scores for quality of life variables at entry. There was a possible link, in the orthosis group, between improvement and pain confined to the rear-foot region.

CONCLUSIONS: The mechanisms by which orthotic intervention is effective in improving pain and function in painful, idiopathic pes cavus remain unclear and equivocal. A strong placebo effect may be in place, or perhaps relatively small changes in foot pressure, even those brought about by a flexible insole with limited shock-absorbing properties, is enough to achieve a clinically meaningful change in symptoms.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app